Dermatologic Therapy最新文献

{"title":"Immunological Changes Associated With Jing Si Herbal Tea as a Complementary Therapy in Patients With Psoriasis","authors":"Jyun-Yan Jhan,&nbsp;Sung-Jen Hung","doi":"10.1155/dth/8851395","DOIUrl":"https://doi.org/10.1155/dth/8851395","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by erythematous plaques with silvery scales and potential nail involvement. Jing Si herbal tea (JSHT), a formulation comprising eight medicinal herbs, has been reported to exert anti-inflammatory and immunomodulatory effects through the regulation of proinflammatory cytokines and signaling pathways. This study aimed to evaluate the efficacy and safety of JSHT as a complementary herbal medicine compared with placebo in patients with psoriasis receiving conventional or biologic treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This double-blind randomized controlled trial enrolled 63 patients with psoriasis and was conducted over 3 months at a single medical center.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>JSHT administration was associated with reduced interleukin (IL)-17 and tumor necrosis factor-beta levels in patients receiving conventional therapy and increased IL-10 levels in those receiving biologic therapy. However, no statistically significant differences were observed between the JSHT and placebo groups in clinical outcomes, including the Psoriasis Area and Severity Index (PASI) and body surface area (BSA). Only mild gastrointestinal adverse events were reported in the JSHT group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>JSHT demonstrated immunomodulatory effects and a favorable safety profile when used as a complementary herbal medicine in patients with psoriasis. However, no significant improvement in clinical disease severity was observed, and further studies are warranted to clarify its clinical efficacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8851395","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L-Histidine as a Biologic Modulator and Therapeutic Target for Atopic Dermatitis: A Narrative Review of Mechanisms, Evidence, and Clinical Implications","authors":"Nana-Hawwa Abdul-Rahman,&nbsp;Alice D. Lee,&nbsp;Gerardo Guiltarte,&nbsp;Sonal Choudhary","doi":"10.1155/dth/7236883","DOIUrl":"https://doi.org/10.1155/dth/7236883","url":null,"abstract":"<p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by epidermal barrier dysfunction, immune dysregulation, and intense pruritus. Although existing treatments, including topical corticosteroids, calcineurin inhibitors, and biologic agents, are effective for many patients, concerns regarding long-term safety, cost, and incomplete disease control have driven interest in nonimmunosuppressive and complementary therapeutic strategies. L-histidine is an essential dietary amino acid that has emerged as a potential biologic modulator in AD due to its central role in filaggrin metabolism and natural moisturizing factor (NMF) production. This narrative review synthesizes the current mechanistic, preclinical, and clinical evidence evaluating L-histidine as a therapeutic or adjunctive intervention in AD. L-histidine supports epidermal hydration, pH homeostasis, and barrier integrity through its role as a precursor of filaggrin-derived NMF components. In vitro and skin-equivalent models demonstrate that L-histidine enhances filaggrin processing and improves functional barrier properties. Importantly, mechanistic studies indicate that histidine supplementation does not promote pathological histamine production, alleviating concerns regarding histamine-mediated disease exacerbation. Clinical evidence, though limited to small exploratory trials and case reports, shows reductions in disease severity and pruritus in both pediatric and adult patients receiving oral L-histidine supplementation. However, these findings should be regarded as preliminary rather than conclusive. The magnitude of improvement reported in these small trials has been described by the authors as similar to SCORAD reductions historically reported for mid-potency topical corticosteroids. However, this is a benchmark comparison against external historical literature, not a head-to-head assessment. Since no head-to-head trial has directly compared L-histidine with topical corticosteroids, its efficacy should not be considered equivalent or directly comparable to that of topical corticosteroids. Oral L-histidine has demonstrated a favorable safety and tolerability profile to date, with no serious adverse events reported. L-histidine is a low-cost, well-tolerated, barrier-targeted adjunct with potential utility in AD management. Larger, long-term randomized controlled trials incorporating genetic stratification and combination therapy designs are warranted to better define its optimal role in clinical practice.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7236883","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abrocitinib in Moderate-To-Severe Atopic Dermatitis: A Prospective Real-World Analysis of Long-Term Efficacy, Drug Survival, Safety, and Predictors of Response","authors":"Zheng Li,&nbsp;Yuemeng Wu,&nbsp;Hao Wu,&nbsp;Ye He,&nbsp;Yu Wang,&nbsp;Haihong Qin,&nbsp;Huibin Yin,&nbsp;Shangshang Wang,&nbsp;Ce Wang,&nbsp;Fulun Li,&nbsp;Wei Li,&nbsp;Hui-chun Su,&nbsp;Chaoying Gu","doi":"10.1155/dth/4278463","DOIUrl":"https://doi.org/10.1155/dth/4278463","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Abrocitinib has shown significant efficacy and safety in clinical trials for moderate-to-severe atopic dermatitis (AD), but long-term real-world data are scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To assess the long-term efficacy, predictors of response, and safety profiles associated with abrocitinib treatment in a real-world setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective study enrolled 147 moderate-to-severe AD patients, and physician- and patient-reported outcomes were evaluated at multiple time points.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Abrocitinib rapidly reduced Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), Itch Numeric Rating Scale (Itch-NRS), and body surface area (BSA) from Week 4 throughout Week 52, with 83.1% and 53.2% of patients achieving EASI-75 and EASI-90, respectively, at Week 52. Improvement was less pronounced in the head and neck compared to the trunk and limbs. Shorter disease duration (&lt;<b> </b>84 months) and the absence of allergic comorbidities predicted better long-term response. Patients achieving EASI-75 or EASI-90 by Week 4 were more likely to maintain control at Week 52. Drug survival was 72.7% at Week 52. Adverse events (AEs) occurred in 61.9% of patients, with acneiform eruptions (19.7%) and gastrointestinal symptoms (17.7%) being most common within Week 12. After 12 weeks, hypercholesterolemia, abnormal liver function, and infections increased.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Abrocitinib showed promising long-term efficacy and safety in Chinese patients with moderate-to-severe AD, while consistent lab monitoring is required.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: ChiCTR2200063195</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4278463","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optical Coherence Tomography, Line-Field Confocal Optical Coherence Tomography, and Reflectance Confocal Microscopy in the Diagnosis of Actinic Cheilitis","authors":"Nadia Günther,&nbsp;Sarah Hobelsberger,&nbsp;Anna Büchner,&nbsp;Frank Friedrich Gellrich,&nbsp;Stefan Beissert,&nbsp;Roland Aschoff","doi":"10.1155/dth/3702945","DOIUrl":"https://doi.org/10.1155/dth/3702945","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>A prolonged exposure to ultraviolet radiation from sunlight can cause actinic cheilitis (AC), a chronic inflammatory disease of the lip. Although AC is typically a clinical diagnosis, a punch biopsy might be necessary to exclude the possibility of squamous cell carcinoma (SCC), particularly in hyperkeratotic lesions. While optical coherence tomography (OCT) and Line-field optical coherence tomography (LC-OCT) are well-established diagnostic devices in the detection of actinic keratosis (AK), there have been no reports in the differentiation of AC yet. This study aimed to describe the imaging characteristics of AC using different noninvasive imaging techniques.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eighteen patients with clinical or histopathological diagnosis of AC were examined with dermoscopy, reflectance confocal microscopy (RCM), LC-OCT, and OCT. Imaging criteria were evaluated based on previous reports and compared to one another.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identify common dermoscopic features in AC, including white and red areas (100% of the patients) as well as polymorphic vessels (100% of the patients) and scaling (89% of the patients). In OCT and LC-OCT, a thickened epidermis (100% vs. 94%) and stratum corneum (83% vs 89%) as well as hyperreflective entry signals (89% vs 94%) can be named as frequent criteria, while in RCM and LC-OCT an atypical honeycomb pattern (both 100%) and marked vascularization appear to be common features.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings underscore the value of noninvasive imaging in the diagnosis of AC and highlight characteristic features that can aid diagnostic confirmation, especially when clinical presentation is inconclusive.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3702945","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Topical Corticosteroid Phobia in Patients With Atopic Dermatitis, Psoriasis, or Vulvar Lichen Sclerosus: A Cross-Sectional Study on Psychological and Disease-Related Factors","authors":"Luigi Zerbinati,&nbsp;Maria Elena Flacco,&nbsp;Lucrezia Pacetti,&nbsp;Valentina Resta,&nbsp;Anastasia Troìa,&nbsp;Monica Corazza,&nbsp;Rosangela Caruso,&nbsp;Stefano Tugnoli,&nbsp;Giovanni Cioni,&nbsp;Alessandro Borghi","doi":"10.1155/dth/7233594","DOIUrl":"https://doi.org/10.1155/dth/7233594","url":null,"abstract":"<p>Topical corticosteroid phobia (TCP) is a widespread phenomenon that can reduce therapeutic adherence and worsen dermatological conditions. However, the underlying causes remain unclear. This study analyzed the prevalence and determinants of TCP through a cross-sectional survey involving 194 patients with three dermatological conditions: psoriasis (PsO), vulvar lichen sclerosus (VLS), and atopic dermatitis (AD). TCP levels were assessed using the TOPICOP questionnaire; furthermore, other questionnaires were administered: NRS, BSI-53, Brief-IPQ, eHEALS, Sci-Pop, and METER. Patients with AD exhibited the highest TCP levels, followed by those with PsO and, lastly, VLS patients. Longer disease duration correlated with higher TCP levels. Being single was associated with lower TCP levels. Patients screened positive for psychopathology had significantly higher levels of TCP and corticosteroid-related worries compared to healthy controls. Regression models indicated that specific illness beliefs significantly predicted TCP levels, whereas general psychopathology did not. Thus, our findings highlight the role of specific illness beliefs in shaping TCP, rather than psychopathology. Higher TCP levels observed in AD patients may be linked to chronic-relapsing nature of the disease. Understanding TCP is essential for developing targeted educational strategies and improving adherence to dermatological treatments, in order to enhance therapeutic outcomes. Excessive fear of corticosteroid use is frequent across various medical disciplines; particularly, TCP is a relevant issue in dermatology, since topical corticosteroids represent the first-line treatment for most skin disorders. This attitude can lead to poor treatment adherence and, consequently, to suboptimal therapeutic outcomes. Understanding the underlying causes of TCP is important in order to develop targeted educational strategies, since it is up to healthcare providers to give patients explanations and reassurances about harmlessness of topical corticosteroids, if administered as indicated.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7233594","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Vibration Anesthesia During Cryotherapy for Common Skin Lesions: A Prospective Randomized Split-Body Study","authors":"Ka Wing Cheung,&nbsp;Hok Fai Cheng,&nbsp;Johnny Yau-Cheung Chang,&nbsp;Shun Chin Ng,&nbsp;Fong Cheng Francis Ip,&nbsp;Ching Kong Stanley Ho","doi":"10.1155/dth/6734028","DOIUrl":"https://doi.org/10.1155/dth/6734028","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the efficacy, tolerability, and safety of vibration anesthesia in reducing pain during cryotherapy for common skin lesions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A prospective randomized split-body study was conducted on 138 patients with at least two similar lesions. One lesion received vibration-assisted cryotherapy, while the paired lesion received control cryotherapy. Pain scores were assessed using a visual analogue scale (VAS), and subgroup analyses were performed based on patients’ demographic data and the lesion characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Vibration-assisted cryotherapy produced lower VAS pain scores than control cryotherapy (median 4 [IQR 2–5] vs 6 [IQR 4–8]; median paired difference −2.0 [IQR −3 to −1]; Wilcoxon signed-rank test <i>p</i> &lt; 0.001). In the GEE model accounting for paired lesions, vibration was associated with a 2.261-point lower VAS score (<i>β</i> −2.261, 95% CI −2.514 to −2.007; <i>p</i> &lt; 0.001). Patient-reported effectiveness was favorable, with 68% rating the intervention as effective or very effective. Notably, 86% of participants expressed a preference to use vibration anesthesia in future cryotherapy sessions. No serious adverse effects were reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vibration anesthesia during cryotherapy produced lower immediate pain scores with few transient device-related complaints. These findings support further investigation and clinical consideration of vibration anesthesia as an adjunct for cryotherapy pain management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6734028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Long-Term Effectiveness of Ixekizumab in Chinese Patients With Moderate-to-Severe Psoriasis: A Retrospective Data Analysis","authors":"Zhihui Yang,&nbsp;Nan Yu,&nbsp;Xiaojing Kang,&nbsp;Ping Wang,&nbsp;Yuyi Wang,&nbsp;Chaochao Chen,&nbsp;Tao Li,&nbsp;Jianjian Zhu,&nbsp;Xuan Wang,&nbsp;Jinnan Li,&nbsp;Hanxi Zhang,&nbsp;Guanshen Dou,&nbsp;Ruoyu Li,&nbsp;Hang Li","doi":"10.1155/dth/7292588","DOIUrl":"https://doi.org/10.1155/dth/7292588","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To assess the real-world long-term treatment effectiveness of ixekizumab (IXE) in Chinese patients with moderate-to-severe psoriasis (msPsO).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study used a Chinese national psoriasis registry database to retrospectively analyze data on patients initiating IXE treatment between 2020 and 2024. Baseline patient characteristics, treatment information, and treatment responses at Weeks 24, 48, 60, and 104 were extracted for data analysis. Descriptive statistics were used to summarize the baseline patient characteristics and treatment responses based on measures such as the Psoriasis Area and Severity Index (PASI). Multiple logistic regression analyses were conducted to explore associations between patient characteristics and PASI response outcomes, including PASI 75, PASI 90, and PASI 100, at each time point.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 415 msPsO patients from 44 hospitals were included (mean age ± standard deviation [SD]: 43.0 ± 14.8 years, male: 72.5%, overweight/obesity: 45.5%, and severe psoriasis: 83.9%). IXE showed sustained effectiveness across all four prespecified time points: PASI 75 response rates were 86.2% at Week 24 (<i>N</i> = 311), 83.7% at Week 48 (<i>N</i> = 178), 85.3% at Week 60 (<i>N</i> = 136), and 87.1% at Week 104 (<i>N</i> = 70); PASI 90 response rates were 74.3%, 71.9%, 71.3%, and 67.1%, respectively; and PASI 100 response rates were 58.5%, 57.9%, 56.6%, and 47.1%, respectively. Multiple logistic regression analyses showed that overweight/obesity (48-week PASI 75: odds ratio [OR] = 0.313, <i>p</i> = 0.047), prior biologic therapy (48-week PASI 75: OR = 0.045, <i>p</i> = 0.010; 60-week PASI 75: OR = 0.046, <i>p</i> = 0.014), and urban employee basic medical insurance (48-week PASI 75: OR = 4.263, <i>p</i> = 0.011; 48-week PASI 90: OR = 2.841, <i>p</i> = 0.016; 60-week PASI 90: OR = 2.597, <i>p</i> = 0.042; 60-week PASI 100: OR = 2.384, <i>p</i> = 0.047) were significantly associated with PASI responses. At Week 104, no significant association was found between the baseline characteristics and PASI responses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This real-world study showed sustained reduction in psoriasis severity in the long term among IXE-treated Chinese patients with msPsO, mirroring clinical trials.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7292588","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Narrowband Ultraviolet B Phototherapy in Early Mycosis Fungoides Is Associated With Morphometric Histological Characteristics","authors":"Ilan Vashurin,&nbsp;Gil Goldinger,&nbsp;Lotan Levin,&nbsp;Karin Warshavsky,&nbsp;Felix Pavlotsky,&nbsp;Iris Barshack,&nbsp;Aviv Barzilai","doi":"10.1155/dth/7383380","DOIUrl":"https://doi.org/10.1155/dth/7383380","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objective</h3>\u0000 \u0000 <p>Narrowband ultraviolet B phototherapy is an established treatment for mycosis fungoides. Data on the factors that predict treatment efficacy are scarce. This study evaluated the association between morphometry of histological parameters and narrowband ultraviolet B efficacy in patients with early-stage mycosis fungoides.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>Morphometric analyses of the degree of spongiosis and the number and size of lymphocytes in the epidermis were conducted retrospectively on biopsies from 57 patients with early-stage mycosis fungoides treated with narrowband ultraviolet B phototherapy. Half of the patients achieved remission after 8 weeks and half did not.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TCR monoclonality, larger epidermal lymphocytes, and higher degree of spongiosis were associated with poor response (<i>p</i> &lt; 0.05) with a sensitivity of 0.82, 0.93, and 0.77, respectively, and a specificity of 0.52, 0.79, and 0.72, respectively. This association was still evident at the end of the phototherapy course. Larger lymphocytes in the epidermis correlated with TCR monoclonality (<i>p</i> = 0.023). Spongiosis was independent of clonality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Morphometric analysis of histological parameters, such as spongiosis and lymphocyte size, is associated with response to narrowband ultraviolet B phototherapy in patients with early-stage mycosis fungoides and may serve as markers for selecting appropriate, individualized treatment plans. Incorporating morphometry into biopsy analysis of early-stage MF may also provide better diagnostic and prognostic accuracy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7383380","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Cholesterol and Statin Therapy for Porokeratosis: A Systematic Review and Exploratory Meta-Analysis","authors":"Maryam Sajjad,&nbsp;Leena Alotaibi,&nbsp;Ahmed N. Alqefari,&nbsp;Norah Aljabr,&nbsp;Ahad Abdulaziz Alruhaymi,&nbsp;Turki Saeed Alkahtani,&nbsp;Ahmed Ayed N. Alanazi,&nbsp;Naif Abed Alshamari,&nbsp;Aliyah Abdulmohsen Alabdulqader,&nbsp;Alanoud Abdullah Al Daej,&nbsp;Nawal Hussain Hibili,&nbsp;Zain Abbara,&nbsp;Elissa Nassif","doi":"10.1155/dth/3648230","DOIUrl":"https://doi.org/10.1155/dth/3648230","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Porokeratosis comprises a group of clinically diverse keratinization disorders unified by the cornoid lamella and increasingly understood through alterations in the mevalonate/cholesterol biosynthesis pathway, including germline variants, somatic second-hit events, clonal mosaicism, and emerging epigenetic mechanisms. These biological insights support investigation of pathogenesis-directed topical statin-based therapy, with or without cholesterol supplementation.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aim&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This systematic review evaluated the reported clinical improvement, safety, and comparative evidence of topical cholesterol/statin combination therapy versus topical statin monotherapy for porokeratosis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;PubMed, Scopus, Web of Science, and Cochrane Library were searched through January 2026. Two independent reviewers screened studies and extracted data on study design, porokeratosis subtype, treatment formulation, clinical outcomes, and adverse events. Because the evidence base consisted largely of small uncontrolled reports with heterogeneous outcome definitions, quantitative summaries were considered exploratory and were interpreted cautiously.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Thirteen studies including 89 patients were included. Most studies were case reports or case series, with limited controlled evidence. Published uncontrolled reports generally described clinical improvement after topical cholesterol/statin therapy, including improvement in erythema and lesion morphology; however, these findings are subject to substantial selection, reporting, and publication bias. Safety data suggested that adverse events were usually mild and local, including application-site discomfort, transient pruritus, erythema, dryness, or eczematous reactions. In the available controlled studies comparing combination therapy with topical statin monotherapy, no statistically significant difference was detected in clinical improvement or severity-score change, although confidence intervals were wide and the analyses were underpowered.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Topical cholesterol/statin therapy remains a biologically plausible and clinically promising approach for porokeratosis, but larger standardized randomized trials are required to define its comparative effectiveness, optimal formulation, and long-term safety.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 &lt;/di","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3648230","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxymatrine-Associated Clinical and Molecular Changes in Psoriasis: An Exploratory WGCNA-Based Translational Study","authors":"Wenfei Luo,&nbsp;Wenbo Cai,&nbsp;Yangxu Ding,&nbsp;Huijuan Shi","doi":"10.1155/dth/4418305","DOIUrl":"https://doi.org/10.1155/dth/4418305","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>This exploratory translational study characterized clinical and molecular changes occurring during oxymatrine (OMT) treatment in psoriasis and prioritized candidate genes within PASI-associated coexpression modules.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>We integrated a cumulative clinical cohort, secondary analysis of previously published WGCNA modules, and independent tissue validation. Fifty-five patients with moderate-to-severe plaque psoriasis, including 16 previously reported patients and 39 subsequently enrolled patients, completed 8 weeks of intravenous OMT (0.6 g/100 mL daily) with paired PASI assessments. Three previously identified PASI-associated modules underwent GO and KEGG enrichment and weighted coexpression network analyses; no new transcriptome sequencing or de novo WGCNA was performed. An independent tissue-validation set evaluated KRTAP8-1, KRTAP13-2, and KRTAP19-1: immunohistochemistry included five paired patients and five healthy controls, whereas RT-qPCR and Western blotting were performed in a subset of three paired patients and three healthy controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the 8-week treatment period, the mean PASI score decreased from 28.82 ± 7.62 to 7.34 ± 4.73, corresponding to a 74.53% within-cohort reduction (<i>p</i> &lt; 0.0001). Functional profiling highlighted distinct exosome/receptor-related, lipid metabolism-PPAR, and keratin filament–ribosome themes across the three PASI-associated modules. Seven network-derived candidates were prioritized: ADH1B, KRTAP19-5, AMTN, KRTAP13-2, KRTAP8-1, KRTAP19-3, and KRTAP19-1. KRTAP8-1, KRTAP13-2, and KRTAP19-1 had lower expression in pretreatment psoriatic lesions than in healthy skin but higher expression after treatment than before treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>OMT treatment was associated with reduced PASI scores and posttreatment changes in selected KRTAP genes. These findings are exploratory and hypothesis-generating and do not establish that OMT caused the clinical improvement or that KRTAP changes mediated the response. Additional controlled clinical studies and functional experiments are required to determine causality and mechanistic relevance.</p>\u0000 \u0000 <p><b>Trail Registration:</b> Chinese Registry of Clinical Trials: ChiCTR-TRC-14004301</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4418305","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}